Abstract What Is Known and Objective There are few reports on the distribution of the
plasma trough concentration (C min) of teicoplanin in patients with augmented renal …

Objective: Because teicoplanin has a long serum half-life, a longer period of time is needed
to achieve a steady-state concentration compared with vancomycin. The administration of an …

The pharmacokinetics of teicoplanin were investigated in 13 subjects with various degrees
of renal impairment using a randomized two‐period crossover design; 11 subjects …

Purpose In clinical practice, teicoplanin (TEIC) is typically administered at a trough
concentration of 15–40 µg/mL. TEIC has a protein binding rate of approximately 90%, and its …

Teicoplanin has a long serum half-life, and therefore it takes time to reach a steady-state
concentration. An initial loading procedure has been recommended for teicoplanin to enable …

We evaluated the clinical efficacy and safety of teicoplanin according to the
pharmacokinetics (PK) therapeutic level achieved in patients with renal dysfunction. Target …

Background: A trough concentration of> 20 mg/L is considered the optimal dosage of
teicoplanin required to ensure early therapeutic effects against methicillin-resistant …

In the treatment of severe MRSA infections such as endocarditis, more than 20 mg/L of
plasma trough concentration (C min) is recommended for teicoplanin; however, in the …

The pharmacokinetic profile of teicoplanin, a new glycopeptide antibiotic active against
Gram-positive aerobic and anaerobic bacteria, was studied in 5 healthy male volunteers and …

Objective Teicoplanin is widely used for the treatment of severe gram-positive infection,
aiming to achieve trough serum levels of 20–60 mg/L for patients with severe infection. A …